Cognition Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics for age-related degenerative diseases, CNS disorders, and retinal conditions where approved treatments are limited or unavailable. The company's lead candidate, zervimesine, is an orally delivered drug designed to protect neuronal synapses by preventing pathogenic protein oligomers from binding to neuronal receptors, with clinical development focused on Alzheimer's disease, dementia with Lewy bodies, and geographic atrophy. Cognition has no marketed products or commercial sales; the company is funded primarily through non-dilutive grants from the National Institute on Aging to support clinical trials, and retains worldwide rights to zervimesine with plans to pursue commercialization through partnerships, internal sales capabilities, or licensing arrangements depending on market opportunity.